{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:22:12Z","timestamp":1760145732810,"version":"build-2065373602"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012155","name":"National Institute for Medical Research Development","doi-asserted-by":"publisher","award":["957777"],"award-info":[{"award-number":["957777"]}],"id":[{"id":"10.13039\/501100012155","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012155","name":"National Institute for Medical Research Development","doi-asserted-by":"publisher","award":["957777"],"award-info":[{"award-number":["957777"]}],"id":[{"id":"10.13039\/501100012155","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Microbial Pathogenesis"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.micpath.2021.104807","type":"journal-article","created":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T21:42:20Z","timestamp":1613684540000},"page":"104807","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["The immunity of the recombinant prokaryotic and eukaryotic subunit vaccines against cutaneous leishmaniasis"],"prefix":"10.1016","volume":"153","author":[{"given":"Samira","family":"Salari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iraj","family":"Sharifi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehdi","family":"Bamorovat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9066-1034","authenticated-orcid":false,"given":"Pooya","family":"Ghasemi Nejad Almani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.micpath.2021.104807_bib1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0035671","article-title":"Leishmaniasis worldwide and global estimates of its incidence","volume":"7","author":"Alvar","year":"2012","journal-title":"PloS One"},{"key":"10.1016\/j.micpath.2021.104807_bib2","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.vaccine.2007.11.021","article-title":"Heterologous prime-boost vaccination with a non-replicative vaccinia recombinant vector expressing LACK confers protection against canine visceral leishmaniasis with a predominant Th1-specific immune response","volume":"26","author":"Ramos","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.micpath.2021.104807_bib3","doi-asserted-by":"crossref","first-page":"19505","DOI":"10.2807\/ese.15.10.19505-en","article-title":"Leishmaniasis emergence in europe","volume":"15","author":"Ready","year":"2010","journal-title":"Euro Surveill. : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin"},{"key":"10.1016\/j.micpath.2021.104807_bib4","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0264-410X(01)00341-3","article-title":"Attenuated Toxoplasma gondii ts-4 mutants engineered to express the Leishmania antigen KMP-11 elicit a specific immune response in BALB\/c mice","volume":"20","author":"Ram\u00edrez","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.micpath.2021.104807_bib5","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/j.1365-4632.2007.03154.x","article-title":"Clinical manifestations and classification of Old World cutaneous leishmaniasis","volume":"46","author":"Akilov","year":"2007","journal-title":"Int. J. Dermatol."},{"key":"10.1016\/j.micpath.2021.104807_bib6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005527","article-title":"A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: first-in-human trial of Chad63-KH","volume":"11","author":"Osman","year":"2017","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.micpath.2021.104807_bib7","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1016\/j.vaccine.2006.11.057","article-title":"Safety trial using the Leishmune vaccine against canine visceral leishmaniasis in Brazil","volume":"25","author":"Parra","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.micpath.2021.104807_bib8","doi-asserted-by":"crossref","first-page":"291","DOI":"10.4161\/hv.5.5.7607","article-title":"Vaccines and vaccination strategies against human cutaneous leishmaniasis","volume":"5","author":"Okwor","year":"2009","journal-title":"Hum. Vaccine"},{"key":"10.1016\/j.micpath.2021.104807_bib9","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1128\/CMR.14.2.229-243.2001","article-title":"Leishmaniasis: current status of vaccine development","volume":"14","author":"Handman","year":"2001","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.micpath.2021.104807_bib10","doi-asserted-by":"crossref","first-page":"3642","DOI":"10.1016\/j.vaccine.2005.02.015","article-title":"Leishmanization: use of an old method for evaluation of candidate vaccines against leishmaniasis","volume":"23","author":"Khamesipour","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.micpath.2021.104807_bib11","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1016\/j.vaccine.2005.11.061","article-title":"The FML-vaccine (Leishmune) against canine visceral leishmaniasis: a transmission blocking vaccine","volume":"24","author":"Saraiva","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.micpath.2021.104807_bib12","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.1016\/j.vaccine.2019.04.068","article-title":"Leishmania major p27 gene knockout as a novel live attenuated vaccine candidate: protective immunity and efficacy evaluation against cutaneous and visceral leishmaniasis in BALB\/c mice","volume":"37","author":"Elikaee","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.micpath.2021.104807_bib13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0002751","article-title":"Enhanced protective efficacy of nonpathogenic recombinant leishmania tarentolae expressing cysteine proteinases combined with a sand fly salivary antigen","volume":"8","author":"Zahedifard","year":"2014","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.micpath.2021.104807_bib14","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.4049\/jimmunol.175.4.2517","article-title":"IL-10 from regulatory T cells determines vaccine efficacy in murine Leishmania major infection","volume":"175","author":"Stober","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.micpath.2021.104807_bib15","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1038\/s41467-020-17154-z","article-title":"A second generation leishmanization vaccine with a markerless attenuated Leishmania major strain using CRISPR gene editing","volume":"11","author":"Zhang","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.micpath.2021.104807_bib16","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.molimm.2016.06.014","article-title":"A vaccine combining two Leishmania braziliensis proteins offers heterologous protection against Leishmania infantum infection","volume":"76","author":"Duarte","year":"2016","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.micpath.2021.104807_bib17","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.molimm.2015.08.001","article-title":"Leishmania tarentolae secreting the sand fly salivary antigen PpSP15 confers protection against Leishmania major infection in a susceptible BALB\/c mice model","volume":"67","author":"Katebi","year":"2015","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.micpath.2021.104807_bib18","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines7040183","article-title":"Immunization with the HisAK70 DNA vaccine induces resistance against leishmania amazonensis infection in BALB\/c mice","volume":"7","author":"Mart\u00ednez-Rodrigo","year":"2019","journal-title":"Vaccines"},{"key":"10.1016\/j.micpath.2021.104807_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000484","article-title":"Vector transmission of leishmania abrogates vaccine-induced protective immunity","volume":"5","author":"Peters","year":"2009","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.micpath.2021.104807_bib20","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1586\/14760584.2014.894467","article-title":"Identifying vaccine targets for anti-leishmanial vaccine development","volume":"13","author":"Sundar","year":"2014","journal-title":"Expet Rev. Vaccine"},{"key":"10.1016\/j.micpath.2021.104807_bib21","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.4049\/jimmunol.147.10.3538","article-title":"The Leishmania donovani lipophosphoglycan T lymphocyte-reactive component is a tightly associated protein complex","volume":"147","author":"Jardim","year":"1991","journal-title":"J. Immunol."},{"issue":"Pt 1","key":"10.1016\/j.micpath.2021.104807_bib22","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1042\/bj3050315","article-title":"Cloning and structure-function analysis of the Leishmania donovani kinetoplastid membrane protein-11","volume":"305","author":"Jardim","year":"1995","journal-title":"The Biochemical journal"},{"key":"10.1016\/j.micpath.2021.104807_bib23","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1016\/j.vaccine.2013.02.025","volume":"31","author":"Guha","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.micpath.2021.104807_bib24","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1084\/jem.186.7.1137","article-title":"Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major","volume":"186","author":"Gurunathan","year":"1997","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.micpath.2021.104807_bib25","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1128\/IAI.70.6.3122-3129.2002","article-title":"LACK-specific CD4(+) T cells that induce gamma interferon production in patients with localized cutaneous leishmaniasis during an early stage of infection","volume":"70","author":"Bourreau","year":"2002","journal-title":"Infect. Immun."},{"key":"10.1016\/j.micpath.2021.104807_bib26","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.molimm.2018.08.004","article-title":"Induction of protective cellular immune responses against experimental visceral leishmaniasis mediated by dendritic cells pulsed with the N-terminal domain of Leishmania infantum elongation factor-2 and CpG oligodeoxynucleotides","volume":"103","author":"Agallou","year":"2018","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.micpath.2021.104807_bib27","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1128\/JCM.40.1.210-215.2002","article-title":"Comparison of six PCR methods using peripheral blood for detection of canine visceral leishmaniasis","volume":"40","author":"Lachaud","year":"2002","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.micpath.2021.104807_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0132794","article-title":"Evaluation of live recombinant nonpathogenic leishmania tarentolae expressing cysteine proteinase and A2 genes as a candidate vaccine against experimental canine visceral leishmaniasis","volume":"10","author":"Shahbazi","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.micpath.2021.104807_bib29","doi-asserted-by":"crossref","first-page":"7377","DOI":"10.1007\/s00253-016-7712-4","article-title":"Leishmania-based expression systems","volume":"100","author":"Taheri","year":"2016","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"10.1016\/j.micpath.2021.104807_bib30","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s00418-016-1526-4","article-title":"Eukaryotic protein glycosylation: a primer for histochemists and cell biologists","volume":"147","author":"Corfield","year":"2017","journal-title":"Histochem. Cell Biol."},{"key":"10.1016\/j.micpath.2021.104807_bib31","doi-asserted-by":"crossref","first-page":"e2174","DOI":"10.1371\/journal.pntd.0002174","article-title":"Development of novel prime-boost strategies based on a tri-gene fusion recombinant L. tarentolae vaccine against experimental murine visceral leishmaniasis","volume":"7","author":"Saljoughian","year":"2013","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.micpath.2021.104807_bib32","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.1574-695X.2009.00607.x","article-title":"Correlation of parasitic load with interleukin-4 response in patients with cutaneous leishmaniasis due to Leishmania tropica","volume":"57","author":"Kumar","year":"2009","journal-title":"FEMS Immunol. Med. Microbiol."},{"key":"10.1016\/j.micpath.2021.104807_bib33","doi-asserted-by":"crossref","first-page":"893","DOI":"10.3389\/fimmu.2017.00893","article-title":"Effects of bone marrow mesenchymal stromal cell therapy in experimental cutaneous leishmaniasis in BALB\/c mice induced by leishmania amazonensis","volume":"8","author":"Pereira","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.micpath.2021.104807_bib34","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.cellimm.2017.11.001","article-title":"Recombinant prohibitin protein of Leishmania infantum acts as a vaccine candidate and diagnostic marker against visceral leishmaniasis","volume":"323","author":"Dias","year":"2018","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.micpath.2021.104807_bib35","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.ijpara.2008.11.009","article-title":"The cytosolic tryparedoxin of Leishmania infantum is essential for parasite survival","volume":"39","author":"Romao","year":"2009","journal-title":"Int. J. Parasitol."},{"key":"10.1016\/j.micpath.2021.104807_bib36","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1007\/s00436-018-5915-6","article-title":"A lentiviral vaccine expressing KMP11-HASPB fusion protein increases immune response to Leishmania major in BALB\/C","volume":"117","author":"Mortazavidehkordi","year":"2018","journal-title":"Parasitol. Res."}],"container-title":["Microbial Pathogenesis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0882401021000796?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0882401021000796?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:38:32Z","timestamp":1760110712000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0882401021000796"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":36,"alternative-id":["S0882401021000796"],"URL":"https:\/\/doi.org\/10.1016\/j.micpath.2021.104807","relation":{},"ISSN":["0882-4010"],"issn-type":[{"type":"print","value":"0882-4010"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The immunity of the recombinant prokaryotic and eukaryotic subunit vaccines against cutaneous leishmaniasis","name":"articletitle","label":"Article Title"},{"value":"Microbial Pathogenesis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.micpath.2021.104807","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104807"}}